RLN1: A Potential Drug Target for Cancer, Cardiovascular Disease and Neurodegenerative Disorders

Target Name: RLN1

NCBI ID: G6013

RLN1

RLN1: A Potential Drug Target for Cancer, Cardiovascular Disease and Neurodegenerative Disorders

Relaxin 1 (RLN1) is a protein that is expressed in various tissues throughout the body, including the uterus, bone marrow, and fat cells. It is a member of the Transforming Growth Factor-beta (TGF-beta) family, which is a well-known signaling pathway that regulates cell growth, differentiation, and survival.

While RLN1 is not a well-known drug target by itself, it is a potential biomarker for several diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. Several studies have identified potential links between RLN1 and these diseases, and researchers are actively exploring its potential as a drug target.

One of the main studies that has identified a potential link between RLN1 and cancer is the case of breast cancer. Several studies have shown that RLN1 is often overexpressed in breast cancer cells, and that this overexpression is associated with poor prognosis and increased risk of recurrence.

Another potential link between RLN1 and cancer is its role in the development of neurodegenerative disorders. RLN1 has been shown to be involved in the development of several neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. This suggests that RLN1 may be a potential drug target for these disorders.

In addition to its potential links to cancer and neurodegenerative disorders, RLN1 is also a potential biomarker for cardiovascular disease. Several studies have shown that RLN1 is expressed in the heart and that it is involved in the development of cardiovascular disease. This suggests that RLN1 may be a potential drug target for cardiovascular disease.

Overall, while RLN1 is not a well-known drug target by itself, it is a potential biomarker for several diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. Further research is needed to fully understand its potential as a drug target and to determine its utility in these areas.

Protein Name: Relaxin 1

Functions: Relaxin is an ovarian hormone that acts with estrogen to produce dilatation of the birth canal in many mammals. May be involved in remodeling of connective tissues during pregnancy, promoting growth of pubic ligaments and ripening of the cervix

The "RLN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RLN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets